Phosphate control in dialysis
- PMID: 24133374
- PMCID: PMC3797240
- DOI: 10.2147/IJNRD.S35632
Phosphate control in dialysis
Abstract
Prevention and correction of hyperphosphatemia is a major goal of chronic kidney disease-mineral and bone disorder (CKD-MBD) management, achievable through avoidance of a positive phosphate balance. To this aim, optimal dialysis removal, careful use of phosphate binders, and dietary phosphate control are needed to optimize the control of phosphate balance in well-nourished patients on a standard three-times-a-week hemodialysis schedule. Using a mixed diffusive-convective hemodialysis tecniques, and increasing the number and/or the duration of dialysis tecniques are all measures able to enhance phosphorus (P) mass removal through dialysis. However, dialytic removal does not equal the high P intake linked to the high dietary protein requirement of dialysis patients; hence, the use of intestinal P binders is mandatory to reduce P net intestinal absorption. Unfortunately, even a large dose of P binders is able to bind approximately 200-300 mg of P on a daily basis, so it is evident that their efficacy is limited in the case of an uncontrolled dietary P load. Hence, limitation of dietary P intake is needed to reach the goal of neutral phosphate balance in dialysis, coupled to an adequate protein intake. To this aim, patients should be informed and educated to avoid foods that are naturally rich in phosphate and also processed food with P-containing preservatives. In addition, patients should preferentially choose food with a low P-to-protein ratio. For example, patients could choose egg white or protein from a vegetable source. Finally, boiling should be the preferred cooking procedure, because it induces food demineralization, including phosphate loss. The integrated approach outlined in this article should be actively adapted as a therapeutic alliance by clinicians, dieticians, and patients for an effective control of phosphate balance in dialysis patients.
Keywords: dialysis; diet; food preservatives; hyperphosphatemia; phosphate binders; phosphorus.
Similar articles
-
[The contribution of dialysis and laboratoristic methods for the control of phosphates].G Ital Nefrol. 2014 Mar-Apr;31(2):gin/31.2.10. G Ital Nefrol. 2014. PMID: 24777923 Review. Italian.
-
Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.Am J Kidney Dis. 2016 Nov;68(5S1):S24-S32. doi: 10.1053/j.ajkd.2016.05.024. Am J Kidney Dis. 2016. PMID: 27772640 Review.
-
Phosphate control in chronic uremia: don't forget diet.J Nephrol. 2003 Jan-Feb;16(1):29-33. J Nephrol. 2003. PMID: 12649532 Review.
-
Dietary Phosphate and the Forgotten Kidney Patient: A Critical Need for FDA Regulatory Action.Am J Kidney Dis. 2019 Apr;73(4):542-551. doi: 10.1053/j.ajkd.2018.11.004. Epub 2019 Jan 25. Am J Kidney Dis. 2019. PMID: 30686528 Review.
-
The "phosphorus pyramid": a visual tool for dietary phosphate management in dialysis and CKD patients.BMC Nephrol. 2015 Jan 20;16:9. doi: 10.1186/1471-2369-16-9. BMC Nephrol. 2015. PMID: 25603926 Free PMC article.
Cited by
-
Phosphates in medications: Impact on dialysis patients .Clin Nephrol. 2020 Apr;93(4):163-171. doi: 10.5414/CN109853. Clin Nephrol. 2020. PMID: 32049627 Free PMC article.
-
Biochemical markers of mineral bone disorder in South African patients on maintenance haemodialysis.Afr Health Sci. 2017 Jun;17(2):445-452. doi: 10.4314/ahs.v17i2.19. Afr Health Sci. 2017. PMID: 29062340 Free PMC article.
-
Reduction of costs for anemia-management drugs associated with the use of ferric citrate.Int J Nephrol Renovasc Dis. 2014 May 20;7:191-201. doi: 10.2147/IJNRD.S65158. eCollection 2014. Int J Nephrol Renovasc Dis. 2014. PMID: 24899820 Free PMC article.
-
Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.Drugs. 2014 May;74(7):771-92. doi: 10.1007/s40265-014-0215-7. Drugs. 2014. PMID: 24811546 Review.
-
Dietary interventions for mineral and bone disorder in people with chronic kidney disease.Cochrane Database Syst Rev. 2015 Sep 16;2015(9):CD010350. doi: 10.1002/14651858.CD010350.pub2. Cochrane Database Syst Rev. 2015. PMID: 26376110 Free PMC article.
References
-
- Alfrey AC. The role of abnormal phosphorus metabolism in the progression of chronic kidney disease and metastatic calcification. Kidney Int Suppl. 2004;(90):S13–S17. - PubMed
-
- Koleganova N, Piecha G, Ritz E, et al. Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant. 2009;24(8):2488–2496. - PubMed
-
- Pribil AB, Hofer TS, Randolf BR, Rode BM. Structure and dynamics of phosphate ion in aqueous solution: an ab initio QMCF MD study. J Comput Chem. 2008;29(14):2330–2334. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources